Use of Non-Steroidal Anti-Inflammatory Drugs and Prostate Cancer Risk: A Population-Based Nested Case-Control Study

Salaheddin M. Mahmud1,2,3*, Eduardo L. Franco1,4, Donna Turner3, Robert W. Platt4, Patricia Beck5, David Skarsgard6, Jon Tonita7, Colin Sharpe7, Armen G. Aprikian2

1 Department of Oncology, McGill University, Montreal, Canada, 2 Department of Surgery (Urology), McGill University, Montreal, Canada, 3 Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada, 4 Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada, 5 Population Health Branch, Saskatchewan Ministry of Health, Regina, Canada, 6 Division of Radiation Oncology, University of Calgary and Tom Baker Cancer Centre, Calgary, Canada, 7 Population Health Division, Saskatchewan Cancer Agency, Regina, Canada

Abstract

Background: Despite strong laboratory evidence that non-steroidal anti-inflammatory drugs (NSAIDs) could prevent prostate cancer, epidemiological studies have so far reported conflicting results. Most studies were limited by lack of information on dosage and duration of use of the different classes of NSAIDs.

Methods: We conducted a nested case-control study using data from Saskatchewan Prescription Drug Plan (SPDP) and Cancer Registry to examine the effects of dose and duration of use of five classes of NSAIDs on prostate cancer risk. Cases ($N = 9,007$) were men aged $\geq 40$ years diagnosed with prostatic carcinoma between 1985 and 2000, and were matched to four controls on age and duration of SPDP membership. Detailed histories of exposure to prescription NSAIDs and other drugs were obtained from the SPDP.

Results: Any use of propionates (e.g., ibuprofen, naproxen) was associated with a modest reduction in prostate cancer risk (Odds ratio = 0.90; 95%CI 0.84-0.95), whereas use of other NSAIDs was not. In particular, we did not observe the hypothesized inverse association with aspirin use (1.01; 0.95–1.07). There was no clear evidence of dose-response or duration-response relationships for any of the examined NSAID classes.

Conclusions: Our findings suggest modest benefits of at least some NSAIDs in reducing prostate cancer risk.

Introduction

It has been shown that non-steroidal anti-inflammatory drugs (NSAIDs) could prevent the development of colon cancer [1], and possibly other cancers [2,3] including prostate cancer [4]. Proposed mechanisms for these effects, including induction of apoptosis [5] and inhibition of cellular proliferation and angiogenesis [6], occur at least partly through the inhibition of the cyclooxygenase (COX) enzymes involved in prostaglandin synthesis. Over-expression of COX-2 has been observed in prostate cancer cells [7], and higher levels of prostaglandins have been detected in malignant compared to benign prostate tissues [8]. In all 12 animal studies included in a recent review, NSAIDs exhibited inhibitory effects on prostate cancer development and progression to invasive disease [9].

Despite strong laboratory evidence, epidemiological studies of NSAID use and prostate cancer have so far produced conflicting results [4,10,11]. Although most studies reported inverse associations between aspirin use and prostate cancer occurrence, some found positive [12] or no associations [13,14,15,16]. Studies that examined the effect of aspirin use on the occurrence of advanced prostate cancer were more consistent [12,13,14,17,18,19]. Studies that examined the effects of non-aspirin (NSAIDs) were inconsistent with cohort studies generally showing no association and case-control studies suggesting statistically significant inverse associations [4].

Most reviewed studies were limited by exposure and disease misclassification, by limited information on dose and duration of use and by the possibility of screening and other biases [4]. Also, there have been no studies that assessed the effects of individual classes of NSAIDs.
We assessed the effects of dose and duration of use of five chemical classes of NSAIDs on prostate cancer risk using a nested case-control analysis of a historical cohort that was assembled by means of record linkage of several large longitudinal databases of routinely collected health data from the Canadian province of Saskatchewan. To our knowledge, this is the largest study to specifically examine the hypothesis that NSAIDs may reduce the risk of prostate cancer, and the first study in the field to systematically examine the effects of five different classes of NSAIDs on prostate cancer risk, rather than just examine the effects of all NSAIDs or one NSAID.

Methods

Ethics statement

This study was approved by the Ethics Review Boards of McGill University and the University of Saskatchewan. Both boards deemed that obtaining consent from individual participants was not necessary or feasible because this study was based on the analysis of anonymous records obtained from administrative databases that include information on all residents of Saskatchewan.

Data sources

Data were obtained by linkage of Saskatchewan Ministry of Health (SH) databases and the Saskatchewan Cancer Registry (SCR). SH provides publicly funded health insurance coverage, including coverage for prescription drugs and hospital and physician services, to most of the province’s one million residents. Eligibility for coverage is not based on age or income [20]. For administrative purposes, SH maintains several centralized electronic databases that can be linked using a unique health services number.

The Saskatchewan Prescription Drug Plan (SPDP), in operation since 1975, records all pharmacy claims for formulary drugs dispensed to Saskatchewan beneficiaries [20]. The accuracy of the recorded prescription information is high [21]. However, the SPDP lacks information on drugs given during hospitalization or bought over the counter (OTC).

All cancers occurring in the study cohort were identified using the population-based SCR, in operation since 1932. Because reporting of cancer cases is mandated by law, cancer registration is virtually complete in Saskatchewan [22]. Most (97%) cases are pathologically-confirmed, and fewer than 3% of registrations originate from death certificates [22]. For the cases, we also had access to detailed clinical information, including stage, Gleason score and results of PSA testing, which was obtained by abstracting clinical charts of all included prostate cancer cases as part of another research project. The methods of that project are documented in detail elsewhere [23].

Information on comorbidity and indication of NSAID use (e.g., diabetes, ischemic heart disease, arthritis, and prostatitis) and on utilization of health care services including urological procedures (Table 1) was obtained from SH hospital separation and physician services databases which, since 1971, recorded most services provided by Saskatchewan hospitals and physicians. The collected data include diagnostic and treatment information including a primary diagnosis, coded using the International Classification of Diseases, Ninth Revision (ICD-9), and service or procedure codes [20]. We used several previously validated algorithms [24] to identify cases of chronic diseases in our cohort (Table 1).

Historical cohort

The study cohort consisted of all men aged 40 years or older who were registered with SH during 1985–2000. Cohort members were followed from the latest of the study start date (January 1, 1985), their 40th birthday or the date of immigration to Saskatchewan until the study end date (December 31, 2000), or the date of diagnosis of prostate cancer, death or emigration, whichever occurred first. The population registry of SH, which tracks eligibility for health insurance coverage [20], was used to determine cohort members’ vital and migration status.

Definition of cases and controls

To be eligible for inclusion in the nested case-control analysis, a participant must have been [1] free of cancer (except non-melanoma skin cancer) before the index date, defined as the date of diagnosis for a case or the date of diagnosis of the matching case for a control; and [2] a beneficiary of prescription drug coverage for a minimum of 5 years prior to his index date (to ensure that all participants had a reasonable opportunity to fill NSAID prescriptions before the index date). Registered Indians and other federal beneficiaries (9% of the population) were excluded because information about their drug use is not captured in the SPDP [20].

The cases group included all men (N = 9,907) in the study cohort who had a diagnosis of primary prostatic carcinoma (ICD-Oncology code C61; morphology codes: 8140/3, 8010/3, and 8000/3). Using incidence density sampling [25], we randomly selected up to four controls (N = 35,891) for each case from among eligible cohort members, matched on age (±1 year) and duration of SPDP membership.

Measurement of prescription drug use

For each participant, detailed histories of exposure to dispensed NSAIDs and 18 other drug classes were obtained from the SPDP for the period between January 1, 1976, or the coverage initiation date, whichever was later, and the index date. The length of these histories was ≥10 years in 98.5% of participants (median 19, range 5–27). The WHO Anatomic Therapeutic Chemical (ATC) classification [26] was used to classify drugs, e.g., NSAIDs were defined as all drugs in the Saskatchewan drug formulary with ATC codes M01A* or N02BA*. NSAIDs were further classified into seven different chemical classes (Table 1). To facilitate comparisons with previous studies, NSAIDs were also classified, in separate analyses, into aspirin and non-aspirin NSAIDs (NA-NSAIDs).

Exposure to each class of NSAIDs was characterized in two ways: (1) as a binary (“any use”) variable indicating whether a participant ever filled a prescription of any drug in the index class at any time during his exposure history. (2) As an ordinal variable representing the quintiles of the average annual dose of the index class calculated by dividing the total dispensed quantity of the class by its overall duration of use (measured from the dispensing date of the first prescription that included a drug in that class). All drug use in the year immediately prior to the index date was excluded to avoid protopathic bias [27].

Because different drugs in the same class may have different pharmacologic potency, the total dispensed quantity for each drug was expressed as a proportion of the WHO’s defined daily dose (DDD) for that drug before summing up all these proportions as the total dispensed quantity of the class (see Table 1 for list of DDDs). The DDD is “the assumed average maintenance dose per day for a drug used for its main indication in adults” [26]. In most analyses, the average annual dose was categorized using the quintiles of the distribution, which were calculated after excluding observations with zero annual dose (“non-users”). Therefore, this
Table 1. Definitions of variables used in the analysis.

| Variable      | Definition                                                                                           |
|---------------|------------------------------------------------------------------------------------------------------|
| **NSAID classes** |                                                                                                      |
| Arylacetate   | Diclofenac (100), Etodolac (400), Indomethacin (100), Sulindac (400), Tolmetin (700), Zomepirac (300) |
| Butyrlpyrazolides | Phenybutazone (300)                                                                                     |
| Fennamates    | Floctafenine (1000), Mefenamic Acid (1000)                                                            |
| Oxicams       | Meloxicam (15), Piroxicam (20)                                                                          |
| Propionates   | Fenoprofen (1200), Flurbiprofen (200), Ibuprofen (1200), Ketoprofen (150), Nabumetone (1000), Naproxen (500) |
| Coxibs        | Celecoxib (200), Rofecoxib (20)                                                                          |
| Aspirin       | Aspirin (3000)                                                                                           |
| **Screening** |                                                                                                      |
| SCREENED      | Binary variable with 1 indicating whether at any point prior to the index date a subject had a physician visit for BPH (ICD-9 code 600.*) or “other disorders of prostate” (602.*); or any point during the 11 years prior to the index date, a subject received at least one prescription for finasteride or an α-blocker or had prostatic ablation or resection, or testing of prostatic secretions. We assumed the men who received these services had at least a DRE. |
| **Medical conditions** |                                                                                                      |
| Diabetes      | ≥2 physician claims with ICD-9 = 250                                                                      |
| Hypertension  | ≥2 physician claims with ICD-9 = 401, 405 OR ≥2 prescriptions for selective β-blockers; thiazides; CCBs-DH; or centrally acting antihypertensives |
| Rheumatoid arthritis | ≥2 physician claims with ICD-9 = 714 OR ≥2 prescriptions for DMRDs or steroids                        |
| Osteoarthritis | ≥3 physician claims with ICD-9 = 710–713; 715–739; No DMRD or steroids                                    |
| Other inflammatory arthritis | ≥3 physician claims with ICD-9 = 710–713; 715–739 AND ≥1 DMRD or steroids                              |
| Cardiac disease/stroke | ≥3 physician claims with ICD-9 = 390–400,402–404,406–459                                           |
| GI bleeding   | ≥1 physician claims with ICD-9 = 578                                                                      |
| Prostatic hypertrophy | ≥1 physician claims with ICD-9 = 600 OR ≥1 prescriptions for finasteride or an α-blocker or ≥1 TURP or ablation |
| Prostatitis   | ≥1 physician claims with ICD-9 = 601 OR ≥1 physician claims for MEPS.                                    |
| **Others**    |                                                                                                      |
| Income status | Binary variable with 1 indicating ever having a prescription flagged for receiving income security benefits. |
| Vasectomy, TURP, Prostatic biopsy, MEPS | Information on these procedures was extracted from a list of all physician-provided urological services (services for which a physician claimed a fee-for-service code under section R of the Saskatchewan Ministry of Health’s “Payment Schedule for Insured Services Provided by a Physician”) since January 1, 1975. |
| Classes of medications | Prostatism agents, androgen antagonists, Lipid lowering agents, Angiotensin converting enzyme inhibitors, Angiotensin receptor blockers, α- and β-blockers, Antihypertensive calcium channel blockers, Centrally acting antihypertensives, Vasodilators, Diuretics, DMRDs, Systemic steroids, Anticoagulants, Cardiac glycosides, Proton pump inhibitors, H2 receptor antagonists, Other ulcer-healing agents. All drugs were classified according to the WHO ATC classification (see text). |

a) For each NSAID, the WHO’s defined daily dose (DDD) used in the analysis is listed in parenthesis (in milligrams). The DDD is “the assumed average maintenance dose per day for a drug used for its main indication in adults” (WHO Collaborating Centre for Drug Statistics Methodology, 2002). Using DDDs, we effectively weighted the prescribed quantity of each NSAID by its anti-inflammatory potency.

b) Based on the most valid chronic disease identification algorithms (those algorithms with the highest Kappa and Youden’s index values) from a comprehensive review of the literature performed by Lix et al (20).

variable had six levels: the five categories formed by the quintile cutoff points and a reference category formed by non-users.

We did not have information on the daily dose or duration of treatment as recommended by the prescribing clinician. To measure the duration of use, we relied on the fact that for most regular NSAID users, prescriptions were typically filled every 3 months. So for every participant, we divided the exposure history into 3-month periods beginning at the date of first prescription filled by that participant. We then counted the number of such periods that included at least 1 prescription. The duration of use variable (in years) was then computed as the sum of these 3-month periods, and further categorized into 7 categories: 0, 0.25, 0.5, 0.75–1.5, 1.75–3.0, 3.25–6.0 and ≥6.25 years, with cutoff points corresponding to the 50th, 75th, 90th, 95th, 99th percentiles of the duration of aspirin use variable.

Statistical analysis

We used conditional logistic regression (CLR) to model the effects of NSAID use on prostate cancer risk while accounting for matching and other confounding variables. The final models were adjusted for screening predictors and, when appropriate, for use of other classes of NSAIDs.

We lacked information on PSA testing among the controls; so instead we adjusted for three variables believed to be associated with heightened screening [28]: ever having seen a urologist in the 1–11 years prior to the index date (i.e. excluding the year immediately prior to the index date); volume of family physician visits in the 5 years prior to the index date; and a composite binary variable (SCREENED) which took the value of 1 if a participant was diagnosed with a prostatic condition other than prostate cancer or received a diagnostic or therapeutic intervention for such a condition (see Table 1 for
Given the long exposure histories in this cohort, the NSAID users group will naturally include participants with highly variable exposure histories. To reduce the effect of this heterogeneity, and to assess for the presence of an “induction period” for NSAID effects (the time interval between an exposure exerting its causal effects and disease initiation or prevention [30]), analyses were repeated after dividing the exposure history into six successive periods: the first spanned the 12-month period prior to the index date. The other periods spanned 5 years each and were as follows: 1.1–6, 6.1–11, 11.1–16, 16.1–21, 21.1–26 years. A separate exposure index was computed for each period by limiting exposure measurements to prescriptions dispensed during that period [31]. As before, CLR models were used to estimates ORs associated with drug use in each period with mutual adjustment for exposure in other periods as well as adjustment for screening predictors.

Results

Most (90%) cases were older than 65 (median age = 73), and were mostly (83%) diagnosed during the 1990s, following the widespread use of PSA screening. At diagnosis, 12% of cases had...

### Table 2. Ever-use of NSAIDs and descriptive statistics of total number of prescriptions among ever-users by case-control status and drug category.

| Drug category | No (%) of ever-users | No. of prescriptions among ever-users |
|---------------|----------------------|--------------------------------------|
|               | Mean | SD  | Q1  | Median | Q3  | Max |
| Aspirin       |      |     |     |        |     |     |
| Controls      | 17469 (48.7) | 6.5 | 13.0 | 1.0    | 2.0 | 5.0 | 238.0 |
| Cases         | 4653 (31.7)  | 6.6 | 13.6 | 1.0    | 2.0 | 5.0 | 172.0 |
| Coxibs        |      |     |     |        |     |     |
| Controls      | 100 (0.3)    | 3.4 | 3.0  | 1.0    | 2.0 | 5.0 | 14.0  |
| Cases         | 27 (0.3)     | 3.1 | 2.2  | 1.0    | 3.0 | 4.0 | 9.0   |
| Arylacetic acids |     |     |     |        |     |     |
| Controls      | 16779 (46.7) | 7.3 | 14.2 | 1.0    | 3.0 | 6.0 | 283.0 |
| Cases         | 4442 (49.3)  | 7.1 | 13.2 | 1.0    | 3.0 | 6.0 | 141.0 |
| Butylpyrazolidines |    |     |     |        |     |     |
| Controls      | 6102 (17.0)  | 2.6 | 4.6  | 1.0    | 1.0 | 2.0 | 122.0 |
| Cases         | 1657 (18.4)  | 2.6 | 4.1  | 1.0    | 1.0 | 2.0 | 81.0  |
| Fenamates     |      |     |     |        |     |     |
| Controls      | 833 (2.3)    | 2.5 | 7.5  | 1.0    | 1.0 | 2.0 | 95.0  |
| Cases         | 234 (2.6)    | 1.9 | 3.3  | 1.0    | 1.0 | 2.0 | 43.0  |
| Oxicams       |      |     |     |        |     |     |
| Controls      | 5976 (16.7)  | 4.9 | 9.1  | 1.0    | 2.0 | 4.0 | 164.0 |
| Cases         | 1620 (18.0)  | 5.0 | 9.2  | 1.0    | 2.0 | 4.0 | 100.0 |
| Propionates   |      |     |     |        |     |     |
| Controls      | 18667 (52.0) | 6.4 | 12.3 | 1.0    | 2.0 | 6.0 | 208.0 |
| Cases         | 4881 (54.2)  | 6.1 | 11.1 | 1.0    | 2.0 | 6.0 | 151.0 |
| NA-NSAIDs     |      |     |     |        |     |     |
| Controls      | 25542 (71.2) | 11.3 | 19.8 | 2.0    | 4.0 | 11.0 | 330.0 |
| Cases         | 6683 (74.2)  | 11.1 | 18.2 | 2.0    | 4.0 | 11.0 | 216.0 |
| NSAIDs        |      |     |     |        |     |     |
| Controls      | 28516 (79.5) | 14.2 | 23.5 | 2.0    | 6.0 | 15.0 | 372.0 |
| Cases         | 7406 (82.2)  | 14.2 | 22.5 | 2.0    | 6.0 | 15.0 | 295.0 |

a) See Table 1 for a list of drugs in each category.

sd: standard deviation; Q1 and Q3: First and third quartiles.
doi:10.1371/journal.pone.0016412.t002
locally-invasive disease (Whitmore-Jewett stage C) and another 15% had metastases (stage D). Gleason score was greater than 7 in 14% of cases.

Overall, 82.2% of cases and 79.5% of controls have received at least one NSAID prescription (Table 2). Propionates, ary lacetic acids and aspirin were the most commonly prescribed NSAIDs. Ignoring matching, there were no significant differences between cases and controls in the median number of filled prescriptions for any of the examined classes (Table 2).

In models accounting for matching but not adjusting for any other confounders (Table 3, left panel), ever filling an NSAID prescription was associated with a small increase in risk (odds ratio [OR] = 1.21; 95% CI 1.13–1.28). Similar results were observed for the different classes of NSAIDs, including aspirin (1.13; 1.08–1.10) and propionates (1.10; 1.05–1.15).

Following adjustment for screening and aspirin use (Table 3, right panel), any use of NA-NSAIDs was inversely associated with prostate cancer risk (0.88; 0.82–0.94). In a model with mutual adjustment for 5 NSAID classes, propionates (0.89; 0.84–0.95) and ary lacetic acids (0.94; 0.80–1.00) were inversely associated with disease risk whereas any use of aspirin was not (OR = 1.01 [95% CI 0.95–1.07]).

A similar pattern was observed when exposure was represented as the quintiles of the average annual dose. Table 4 shows the results from two separate models that included mutual adjustment for quintiles of the average annual dose of five NSAID classes. In one model, dose quintiles were entered as an ordinal variable (a linear term). In the second, each level of the ordinal dose variable was represented in the model with a binary indicator variable. The OR associated with the linear term of aspirin annual dose was 0.99 (0.97–1.01). Aspirin use was not statistically significantly associated with prostate cancer at any dose level. On the other hand, propionate use was inversely associated with prostate cancer risk; linear term = 0.97 (0.96–0.99). Inverse associations were seen at all levels above 1.1 DDDs/year, but there was no clear evidence of a monotonic dose-effect relationship.

Similar results (data not shown) were obtained when the average annual dose variables were categorized using “fixed” cutoff points that were all multiples of 10 DDDs/year, i.e., 2.5, 5, 10, 20 and 40; 10 DDDs/year of NSAID use is equivalent to 1 year use of a once daily dose of 81 milligrams of aspirin). Specifically, for each NSAID class, the annual average dose was categorized into 0 (never-use), 0.1–2.4, 2.5–4.9, 5.0–9.9, 10.0–19.9, 20.0–39.9 and 40.0–79.9 DDDs/year. In these analyses, inverse associations at all levels were observed for propionates. However, there was no clear monotonic dose-effect relationship demonstrated in any of these analyses.

As shown in Table 5, duration of use of aspirin was not associated with prostate cancer risk (linear term OR = 0.99 [0.97–1.02]). Although all levels of the propionate duration of use variable were inversely associated with disease risk, the associations were generally not statistically significant, and there was no clear trend of stronger associations with longer duration of use.

Table 6 shows results of models that included period-specific binary terms for ever-use of each of five classes of NSAIDs. The aim of these analyses was to identify the exposure window (period) that is most likely associated with possible biological effects of NSAID use. The strongest inverse association for aspirin was seen for the period 1.1–6 years before the index date, but there was no discernable pattern to the period-specific ORs, and none of them was statistically significant. For propionates, the strongest inverse association was observed during the 11.1–16 years period, OR = 0.85 (95% CI 0.76–0.94). Strong positive associations were observed for several NSAIDs during the one-year period immediately before the index date, likely due to protopathic bias as NSAIDs are widely used to manage pain, which could be a symptom of undetected cancer. Similar pattern of results was observed when the linear (ordinal) term of the average annual dose (as defined in the dose-effect analysis) was substituted for the binary ever-use term (data not shown).

Discussion

We found that propionate use was consistently inversely related to prostate cancer risk whereas aspirin use was not. The strongest association was observed with propionate use taking place 11–16 years before diagnosis.

Although the bulk of the literature is suggestive of protective effects for aspirin use [4], our results are consistent with those from four large population-based cohort studies [13,14,15,16] in

Table 3. Effect of ever filling a prescription of an NSAID class on the risk of developing prostate cancer.

| Variable     | Unadjusted OR* (95%CI) | P-value | Adjusted OR* (95%CI) | P-value |
|--------------|------------------------|---------|----------------------|---------|
| Aspirin      | 1.13 (1.08–1.18)       | <0.001  | 1.01 (0.95–1.07)     | 0.816   |
| Ary lacetic acids | 1.11 (1.06–1.17)   | <0.001  | 0.94 (0.88–1.00)     | 0.043   |
| Butyl/pyrazolines | 1.10 (1.04–1.17)    | 0.002   | 0.99 (0.92–1.07)     | 0.776   |
| Oxicams      | 1.10 (1.03–1.17)       | 0.002   | 0.96 (0.89–1.04)     | 0.368   |
| Propionates  | 1.10 (1.05–1.15)       | <0.001  | 0.89 (0.84–0.95)     | <0.001  |
| Coxibs       | 1.09 (0.70–1.69)       | 0.712   | Excluded c           |         |
| Fenamates    | 1.12 (0.97–1.30)       | 0.119   | Excluded c           |         |
| NA-NSAIDs    | 1.17 (1.11–1.24)       | <0.001  | 0.88 (0.82–0.94)     | <0.001  |
| NSAIDs       | 1.21 (1.13–1.28)       | <0.001  | 0.87 (0.80–0.94)     | <0.001  |

a) ORs from unadjusted conditional logistic regression models for comparison.

b) Adjusted for ever visited a urologist 1–11 years prior, SCREENED and volume of family physician visits in the 5 years prior to the index date and, when appropriate, for use of other NSAID classes.

c) Fenamates and Coxibs were excluded from this model because of small numbers.

d) From an adjusted model that included terms for NA-NSAIDs and aspirin in addition to screening predictors as above.

Note: Effect estimates throughout the paper have been rounded to two decimal digits. This is not meant to imply that our results are accurate to two decimal digits.
Table 4. Effect of average annual NSAID dose (in DDDs/year; categorized using the quintiles of the distribution) on the risk of developing prostate cancer.

| Variable      | OR (95%CI) | P-value | iOR (95%CI) | P-value |
|---------------|------------|---------|-------------|---------|
| **Aspirin**   |            |         |             |         |
| Linear term   | 0.99 (0.98–1.01) | 0.380   |             |         |
| Quintiles     |            |         |             |         |
| Never-users   | 1.0 (reference) |         |             |         |
| 0.1–0.1       | 1.04 (0.94–1.16) | 0.422   | 1.04 (0.94–1.16) | 0.422 |
| 0.2–0.6       | 1.08 (0.97–1.19) | 0.146   | 1.03 (0.91–1.18) | 0.617 |
| 0.7–1.7       | 0.97 (0.87–1.07) | 0.547   | 0.90 (0.79–1.02) | 0.102 |
| 1.8–4.9       | 1.02 (0.92–1.13) | 0.734   | 1.05 (0.92–1.19) | 0.448 |
| ≥5.0          | 0.93 (0.84–1.03) | 0.158   | 0.91 (0.80–1.03) | 0.147 |
| **Arylacetic acids** |        |         |             |         |
| Linear term   | 0.99 (0.97–1.01) | 0.292   |             |         |
| Quintiles     |            |         |             |         |
| Never-users   | 1.0 (reference) |         |             |         |
| 0.1–1.0       | 0.94 (0.85–1.05) | 0.290   | 0.94 (0.85–1.05) | 0.290 |
| 1.1–2.2       | 0.91 (0.82–1.01) | 0.073   | 0.96 (0.84–1.10) | 0.573 |
| 2.3–4.6       | 0.95 (0.86–1.05) | 0.321   | 1.04 (0.92–1.19) | 0.526 |
| 4.7–12.3      | 0.94 (0.85–1.05) | 0.284   | 0.99 (0.87–1.13) | 0.927 |
| ≥12.4         | 0.97 (0.87–1.09) | 0.615   | 1.03 (0.90–1.17) | 0.648 |
| **Butylpyrazidines** |     |         |             |         |
| Linear term   | 1.00 (0.98–1.02) | 0.932   |             |         |
| Quintiles     |            |         |             |         |
| Never-users   | 1.0 (reference) |         |             |         |
| 0.1–0.5       | 0.99 (0.85–1.16) | 0.929   | 0.99 (0.85–1.16) | 0.929 |
| 0.6–0.8       | 1.03 (0.88–1.20) | 0.751   | 1.03 (0.83–1.28) | 0.767 |
| 0.9–1.5       | 0.98 (0.84–1.14) | 0.782   | 0.95 (0.77–1.18) | 0.667 |
| 1.6–3.0       | 0.86 (0.74–1.01) | 0.070   | 0.88 (0.71–1.10) | 0.263 |
| ≥3.1          | 1.11 (0.95–1.30) | 0.197   | 1.28 (1.04–1.59) | 0.023 |
| **Oxicams**   |            |         |             |         |
| Linear term   | 0.99 (0.96–1.01) | 0.254   |             |         |
| Quintiles     |            |         |             |         |
| Never-users   | 1.0 (reference) |         |             |         |
| 0.1–1.4       | 1.06 (0.90–1.23) | 0.491   | 1.06 (0.90–1.23) | 0.491 |
| 1.5–2.4       | 0.97 (0.83–1.14) | 0.699   | 0.92 (0.74–1.14) | 0.439 |
| 2.5–4.4       | 0.99 (0.85–1.16) | 0.929   | 1.02 (0.82–1.27) | 0.825 |
| 4.5–10.6      | 0.88 (0.75–1.03) | 0.120   | 0.89 (0.72–1.10) | 0.280 |
| ≥10.7         | 0.95 (0.81–1.11) | 0.516   | 1.07 (0.87–1.33) | 0.504 |
| **Propionates** |          |         |             |         |
| Linear term   | 0.97 (0.96–0.99) | 0.004   |             |         |
| Quintiles     |            |         |             |         |
| Never-users   | 1.0 (reference) |         |             |         |
| 0.1–1.1       | 0.92 (0.83–1.01) | 0.092   | 0.92 (0.83–1.01) | 0.092 |
| 1.2–2.5       | 0.88 (0.80–0.98) | 0.017   | 0.97 (0.85–1.10) | 0.588 |
| 2.6–5.1       | 0.91 (0.82–1.01) | 0.072   | 1.03 (0.91–1.17) | 0.641 |
| 5.2–13.2      | 0.88 (0.79–0.97) | 0.012   | 0.96 (0.85–1.09) | 0.543 |
| ≥13.3         | 0.89 (0.80–1.00) | 0.042   | 1.02 (0.90–1.16) | 0.757 |

a) For each class, results from two separate models are reported. In one model, the dose quintiles were entered as an ordinal variable (a linear term). In the second model, each level (quintile) of the ordinal dose variable was represented in the model with a binary indicator variable. In the analyses shown in the left panel, the reference group is men who did not fill any prescriptions of the index class (never-users).

b) Adjusted for ever having visited a urologist 1–11 years prior, SCREENED and volume of family physician visits in the 5 years prior to the index date, and for all NSAID classes listed in the table.

c) iOR: Incremental OR. The ORs in the right panel are incremental ORs from models that contrast the effect at each level with that at the previous level. iORs consistently (at all levels) above (or below) 1.0 suggest a monotonic increasing (or decreasing) dose-response relationship.

doi:10.1371/journal.pone.0016412.t004
### Table 5. Effect of duration of NSAID prescriptions (in years) on the risk of developing prostate cancer.

| Variable* | OR (95%CI)b | P-value | iORc (95%CI) | P-value |
|-----------|-------------|---------|-------------|---------|
| **Aspirin** |             |         |             |         |
| Linear term | 0.99 (0.97–1.02) | 0.594 |             |         |
| Categories |             |         |             |         |
| Never-users | 1.0 (reference) |       |             |         |
| 0.25 | 1.03 (0.96–1.12) | 0.381 | 1.03 (0.96–1.12) | 0.381 |
| 0.5 | 1.14 (1.03–1.26) | 0.014 | 1.10 (0.98–1.23) | 0.097 |
| 0.75–1.5 | 0.96 (0.87–1.06) | 0.400 | 0.84 (0.74–0.95) | 0.007 |
| 1.75–3.0 | 0.87 (0.75–1.01) | 0.059 | 0.91 (0.77–1.06) | 0.233 |
| 3.25–6.0 | 0.91 (0.77–1.07) | 0.262 | 1.05 (0.85–1.29) | 0.668 |
| >6.0 | 1.26 (1.00–1.57) | 0.047 | 1.38 (1.06–1.81) | 0.018 |
| **Arylacetic acids** |             |         |             |         |
| Linear term | 1.00 (0.97–1.02) | 0.656 |             |         |
| Categories |             |         |             |         |
| Never-users | 1.0 (reference) |       |             |         |
| 0.25 | 0.92 (0.85–1.00) | 0.057 | 0.92 (0.85–1.00) | 0.057 |
| 0.5 | 0.97 (0.87–1.08) | 0.577 | 1.05 (0.94–1.18) | 0.402 |
| 0.75–1.5 | 0.96 (0.88–1.06) | 0.428 | 0.99 (0.88–1.12) | 0.897 |
| 1.75–3.0 | 1.02 (0.89–1.17) | 0.801 | 1.06 (0.91–1.22) | 0.452 |
| 3.25–6.0 | 0.91 (0.77–1.08) | 0.295 | 0.89 (0.73–1.10) | 0.281 |
| >6.0 | 1.03 (0.82–1.30) | 0.789 | 1.13 (0.86–1.48) | 0.368 |
| **Butylpyrazolines** |             |         |             |         |
| Linear term | 0.99 (0.95–1.03) | 0.660 |             |         |
| Categories |             |         |             |         |
| Never-users | 1.0 (reference) |       |             |         |
| 0.25 | 0.99 (0.90–1.09) | 0.888 | 0.99 (0.90–1.09) | 0.888 |
| 0.5 | 0.92 (0.78–1.08) | 0.315 | 0.93 (0.77–1.11) | 0.403 |
| 0.75–1.5 | 0.94 (0.79–1.13) | 0.517 | 1.03 (0.81–1.30) | 0.837 |
| 1.75–3.0 | 1.41 (0.99–2.02) | 0.058 | 1.50 (1.01–2.23) | 0.044 |
| 3.25–6.0 | 0.85 (0.46–1.56) | 0.601 | 0.60 (0.30–1.21) | 0.156 |
| >6.0 | 0.29 (0.06–1.37) | 0.118 | 0.34 (0.06–1.81) | 0.204 |
| **Oxicams** |             |         |             |         |
| Linear term | 0.97 (0.94–1.01) | 0.099 |             |         |
| Categories |             |         |             |         |
| Never-users | 1.0 (reference) |       |             |         |
| 0.25 | 1.02 (0.92–1.13) | 0.686 | 1.02 (0.92–1.13) | 0.686 |
| 0.5 | 0.92 (0.78–1.08) | 0.283 | 0.90 (0.75–1.08) | 0.241 |
| 0.75–1.5 | 0.85 (0.72–0.99) | 0.035 | 0.92 (0.74–1.14) | 0.467 |
| 1.75–3.0 | 0.92 (0.72–1.18) | 0.525 | 1.09 (0.82–1.45) | 0.547 |
| 3.25–6.0 | 1.04 (0.73–1.48) | 0.817 | 1.13 (0.74–1.73) | 0.575 |
| >6.0 | 0.76 (0.36–1.60) | 0.468 | 0.73 (0.32–1.65) | 0.448 |
| **Propionates** |             |         |             |         |
| Linear term | 0.98 (0.96–1.00) | 0.029 |             |         |
| Categories |             |         |             |         |
| Never-users | 1.0 (reference) |       |             |         |
| 0.25 | 0.91 (0.84–0.99) | 0.024 | 0.91 (0.84–0.99) | 0.024 |
| 0.5 | 0.96 (0.87–1.07) | 0.483 | 1.06 (0.95–1.18) | 0.301 |
| 0.75–1.5 | 0.88 (0.80–0.96) | 0.005 | 0.91 (0.81–1.02) | 0.099 |
| 1.75–3.0 | 0.92 (0.80–1.06) | 0.235 | 1.05 (0.91–1.21) | 0.509 |
| 3.25–6.0 | 0.93 (0.78–1.11) | 0.444 | 1.01 (0.83–1.24) | 0.891 |
| >6.0 | 0.87 (0.68–1.13) | 0.298 | 0.94 (0.70–1.26) | 0.662 |
Table 5. Cont.

a) For each class, results from two separate models are reported. In one model, the duration of use categories were entered as an ordinal variable (a linear term). In the second model, each level of the ordinal duration of use variable was represented in the model with a binary indicator variable. In the analyses shown in the left panel, the reference group is men who did not fill any prescriptions of the index class (never-users).

b) Adjusted for ever having visited a urologist 1–11 years prior, SCREENED and volume of family physician visits in the 5 years prior to the index date, and to all terms listed in the table.

c) iOR: Incremental OR.

doi:10.1371/journal.pone.0016412.t005

Table 6. Effect of NSAID ever-use in each exposure period (in years before the index date) on the risk of developing total prostate cancer by NSAID category.

| Variable       | OR (95%CI)* | P-value |
|----------------|-------------|---------|
| **Aspirin**    |             |         |
| ≤1             | 1.00 (0.87–1.16) | 0.954   |
| 1.1–6          | 0.93 (0.83–1.03) | 0.157   |
| 6.1–11         | 0.96 (0.87–1.06) | 0.409   |
| 11.1–16        | 1.02 (0.91–1.15) | 0.677   |
| 16.1–21        | 1.10 (0.96–1.27) | 0.161   |
| 21.1–26        | 1.00 (0.79–1.26) | 0.990   |
| **Arylacetincs** |            |         |
| ≤1             | 1.20 (1.06–1.37) | 0.005   |
| 1.1–6          | 0.99 (0.91–1.08) | 0.796   |
| 6.1–11         | 0.99 (0.90–1.09) | 0.813   |
| 11.1–16        | 0.94 (0.84–1.05) | 0.277   |
| 16.1–21        | 0.96 (0.83–1.12) | 0.642   |
| 21.1–26        | 0.77 (0.57–1.05) | 0.098   |
| **Butylpyrazolidines** |      |         |
| ≤1             | 1.35 (0.45–4.05) | 0.589   |
| 1.1–6          | 1.25 (0.89–1.76) | 0.200   |
| 6.1–11         | 1.13 (0.91–1.41) | 0.262   |
| 11.1–16        | 0.79 (0.65–0.97) | 0.022   |
| 16.1–21        | 0.99 (0.80–1.23) | 0.931   |
| 21.1–26        | 1.05 (0.78–1.42) | 0.734   |
| **Oxicams**    |             |         |
| ≤1             | 0.90 (0.61–1.31) | 0.567   |
| 1.1–6          | 0.96 (0.81–1.15) | 0.683   |
| 6.1–11         | 1.01 (0.87–1.18) | 0.886   |
| 11.1–16        | 0.96 (0.81–1.14) | 0.674   |
| 16.1–21        | 0.84 (0.63–1.12) | 0.234   |
| **Propionates** |             |         |
| ≤1             | 1.11 (0.96–1.30) | 0.164   |
| 1.1–6          | 0.93 (0.85–1.01) | 0.098   |
| 6.1–11         | 0.96 (0.88–1.05) | 0.426   |
| 11.1–16        | 0.85 (0.76–0.94) | 0.001   |
| 16.1–21        | 1.05 (0.92–1.20) | 0.439   |
| 21.1–26        | 0.87 (0.68–1.12) | 0.291   |

a) Adjusted for ever visited a urologist 1–11 years prior, SCREENED and volume of family physician visits in the 5 years prior to the index date, and to all terms listed in the table.

doi:10.1371/journal.pone.0016412.t006
error rate, we saw no significant differences from the empirical estimates (data available on request). For propionates, all levels of the average annual dose quintile variable remained inversely related to prostate cancer risk, especially with higher simulated use rates. For both aspirin and propionates, the linear trends were smoother than those observed empirically.

The possibility of confounding should also be considered. We found no evidence that any of a large number of medications and indications and contraindications of NSAID use (Table 1) was a significant confounder. We could not adjust for ethnicity. However, the generation of men included in this study was predominantly Caucasian (most Aboriginal men were excluded), thus any confounding effect is likely small [39]. We have no reason to believe that family history of prostate cancer could be a confounder. We lacked information on putative lifestyle risk factors. In previous studies, adjustment for these factors did not appreciably change the crude estimates [13,19,40]. This is not surprising given the lack of known significant exogenous risk factors for prostate cancer [41]. Although we cannot rule out the possibility of bias due to residual confounding, our sensitivity analyses suggest that even a strong confounder (one associated with a 5-fold increase or decrease in prostate cancer risk) will not fully explain the observed differences between aspirin and propionate use.

The aspirin-propionate differences may also stem from differences in patterns of use of these medications. Among older men, aspirin is prescribed in low doses primarily for cardio-protection whereas propionates are used in full strength doses as analgesic and anti-inflammatory medications. However, our dose-response analysis suggests that propionate use was inversely related to prostate cancer risk at all dose levels whereas aspirin was not.

Finally, the observed differences between aspirin and propionates could be due to genuine heterogeneity in effect reflecting differences in their pharmacokinetics or biological effects. For instance, compared to other NSAIDs, aspirin undergoes an extensive first pass hepatic metabolism following oral administration [19], which may translate into lower availability at the tissue level inside the prostate gland. Aspirin is a potent inhibitor of COX-1 whereas the propionates are potent inhibitors of both COX-1 and COX-2 [42]. This is important because the bulk of the evidence from laboratory studies is consistent with a more important role for COX-2 in prostate carcinogenesis [7,43]. Lastly, it has been suggested that some NSAIDs may have anti-tumour effects independent of COX blockade [44]. For instance, R-flurbiprofen and exisulind, NSAIDs that are not active against COX, have significant anti-neoplastic properties [45]. Also, some anti-tumour effects of NSAIDs are not reversed by the addition of prostaglandins, or seem to occur at tissue concentrations lower than those required for COX inhibition [44]. It is plausible that NSAIDs differ in their ability to induce these COX-independent effects, which may explain some of the differences observed in this study.

In conclusion, we found that use of propionates was associated with a small reduction in prostate cancer risk. There was no clear evidence of dose-response or duration-response relationships with any of the examined NSAID classes. Further studies are needed to confirm the observed associations, and to address important unanswered questions about the specific NSAIDs with the largest benefits, and the optimal dose and duration of use required for maximum benefits [46]. Compared to other novel chemopreventive agents, the toxicity profiles of the classic NSAIDs are generally well understood [1]. However, any potential benefits of NSAID use would have to be carefully weighed against the risks associated with their regular use [47].

Acknowledgments

The authors are greatly indebted to Drs. Deborah Simmons, Harminder Singh, Anita Kozyszkij, Silvia Alessi-Severini and Tom Hassan and Ms. Laura Thompson for valuable comments on the report that formed the basis of this manuscript.

Author Contributions

Conceived and designed the experiments: SMM ELF AGA. Performed the experiments: SMM ELF DT RWP PB DS JT AGA. Analyzed the data: SMM. Contributed reagents/materials/analysis tools: PB DS JT. Wrote the paper: SMM.

References

1. Rostom A, Dube C, Levin G, Tsivtsivadze A, Barrowman N, et al. (2007) Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146: 376–389.
2. Corley DA, Kellkirks K, Verma R, Buffle F (2003) Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124: 47–56.
3. Khuder SA, Mungi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84: 1108–1192.
4. Mahmud SM, Franco EL, Aprikian AG (2010) Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: A meta-analysis. International Journal of Cancer 127: 1600–1609.
5. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, et al. (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397–11403.
6. Kirschbaum A, Liu X, Yao S, Levine AC (2001) The role of cyclooxygenase-2 in prostate cancer. Urology 58: 127–131.
7. Gupta S, Srivastava M, Ahmad N, Bestwick DG, Malik H (2000) Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42: 73–79.
8. Chaudry AA, Wahle KW, McClinton S, Moffat LE (1994) Arachidonic acid activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397–11403.
9. Mahmut SM, Franco EL, Aprikian AG (2006) Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: A meta-analysis. International Journal of Cancer 84: 1108–1192.
10. Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138–146.
11. Paganini-Hill A, Chao A, Ross RK, Henderson BE (1989) Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 299: 1247–1250.
12. Habel LA, Zhao W, Stanford JL (2002) Daily aspirin use and prostate cancer risk in a large, multisite cohort in the US. Cancer Causes Control 13: 427–434.
13. Jacobs EJ, Thun MJ, Bain BR, Rodriguez M, Henley SJ, et al. (2007) A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence. Journal of the National Cancer Institute 99: 608–613.
14. Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, et al. (2002) Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 11: 1108–1111.
15. Risch HA, Howe GR (1998) Non-steroidal anti-inflammatory drug and prostate cancer progression. Int J Cancer 77: 511–515.
16. Downey W, Stang M, Beck P, Osei W, Nichol JL (2007) Health Services Databases in Saskatchewan. In: Brian LS, ed. Pharmacoepidemiology. 4th ed
17. Buzon GJ, Tonita J (2000) Prostate cancer in Saskatchewan Canada, before and during the PSA era. Cancer Causes Control 11: 79–88.
23. Tonita JM, Skraggard D, Mahajarine N (2008) Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era. Cancer Causes and Control.

24. Lix L, Yogendran M, Burchill G, Metge C, McKeen N, et al. (2006) Defining and Validating Chronic Diseases: An Administrative Data Approach. Winnipeg: Manitoba Centre for Health Policy.

25. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS (1992) Selection of Controls in Case-Control Studies: III. Design Options. Am J Epidemiol 135: 1042–1050.

26. WHO Collaborating Centre for Drug Statistics Methodology (2002) ATC Index With DDDs. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology.

27. Salas M, Hofman A, Stricker BH (1999) Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 149: 981–983.

28. Perron L, Bairati I, Moore L, Meyer F (2003) Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 106: 409–415.

29. Shachter S, Rosenthal I, Greenland S (1992) Tests for Trend and Dose Response: Misprediction and Alternatives. Am J Epidemiol 135: 96–104.

30. Rothman KJ (1981) Induction and latent periods. Am J Epidemiol 114: 253–259.

31. Rothman KJ, Greenland S (1998) Modern Epidemiology. Philadelphia: Lipincott-Raven Publishers.

32. Harris RE, Beebe-Donk J, Doss H, Burr DD (2005) Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncology Reports 13: 559–563.

33. Lipworth L, Friis S, Blot WJ, McLaughlin JK, Møllemkjær L, et al. (2004) A population-based cohort study of mortality among users of ibuprofen in Denmark. Am J Ther 11: 156–163.

34. Godfrey PA, Schell MJ (1999) Adjusted odds ratios under nondifferential misclassification: application to prostate cancer. J Clin Epidemiol 52: 129–136.

35. Weiss NS (2003) Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it. Am J Epidemiol 157: 957–961.

36. Platz EA (2007) Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer. Cancer Epidemiology, Biomarkers and Prevention 16: 2175–2180.

37. Varas-Lorenzo C, Castellague J, Stang MR, Tomas L, Aguado J, et al. (2006) Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. Pharmacoeconomics and Drug Safety 17: 842.

38. Greenland S (2005) Multiple-bias modelling for analysis of observational data. Journal of the Royal Statistical Society Series A 168: 267–306.

39. Statistics Canada (2008) Aboriginal Population Profile, 2006 Census. Statistics Canada.

40. Irani J, Raverty V, Pariente JL, Cherrier-Kastler E, Lechevallier E, et al. (2002) Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 168: 1983–1988.

41. Malhau SM (2007) The enigma of prostate cancer: An epidemiologic survey of the etiological models of prostate cancer. International Journal of Cancer Prevention 3: 39–36.

42. Frolich JC (1997) A classification of NSAIIDS according to the relative inhibition of cyclooxygenase isoenzymes. Trends in Pharmacological Sciences 18: 30–34.

43. Narayanan BA, Narayanan NK, Davis L, Nargi D (2006) RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther 5: 1117–1123.

44. Groch S, Maier T, Schäflmann S, Geisslinger G (2006) Cyclooxygenase-2 (COX-2)-Independent Anti-angiogenic Effects of Selective COX-2 Inhibitors. Journal of the National Cancer Institute 98: 736–747.

45. Wechter WJ, Leipold DD, Murray ED, Quiggle D, McCracken JD, et al. (2000) E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 60: 2203–2208.

46. Stock DC, Gromoy PA, Siemens DR, Rohland SL, Song Z (2006) Effects of non-selective non-steroidal anti-inflammatory drugs on the aggressiveness of prostate cancer. The Prostate 66: 1655–1663.

47. Thun MJ, Healy SJ, Patroncino C (2002) Nonsteroidal Anti-Inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues. Journal of the National Cancer Institute 94: 252–266.